Abbott Laboratories (ABT)
NYSE · Healthcare · Medical Devices
Abbott Laboratories is a Healthcare company with a market capitalization of $192.35B, a trailing P/E ratio of 35.7, and a dividend yield of 1.66%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 16, 2026 | $1.15 | $1.15 | +0.0% |
| Q4 2025 | January 22, 2026 | $1.50 | $1.49 | +0.7% |
| Q3 2025 | October 15, 2025 | $1.30 | $1.30 | +0.0% |
| Q2 2025 | July 17, 2025 | $1.26 | $1.26 | +0.0% |
| Q1 2025 | April 16, 2025 | $1.09 | $1.07 | +1.9% |
| Q4 2024 | January 22, 2025 | $1.34 | $1.34 | +0.0% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 24,846,147 | 1.42% | 2.1 | +6.2% |
| June 30, 2026 | 23,387,895 | 1.34% | 1.5 | +6.4% |
| June 15, 2026 | 21,974,266 | 1.26% | 1.8 | -0.3% |
| May 29, 2026 | 22,044,423 | 1.26% | 1.9 | -5.1% |
| May 15, 2026 | 23,222,031 | 1.33% | 1.7 | +3.0% |
| April 30, 2026 | 22,536,486 | 1.29% | 1.5 | +3.6% |
| April 15, 2026 | 21,746,613 | 1.24% | 2.3 | -8.7% |
| March 31, 2026 | 23,825,745 | 1.36% | 1.6 | +19.4% |
Other Medical Devices Stocks
Frequently Asked Questions
What is Abbott Laboratories's market cap?
As of August 13, 2026, Abbott Laboratories (ABT) has a market capitalization of $192.35B.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories trades at a trailing price-to-earnings (P/E) ratio of 35.7. Its forward P/E is 20.0.
Does Abbott Laboratories pay a dividend?
Yes — Abbott Laboratories pays a dividend yielding 1.66%, an annual payout of $2.48 per share.
What sector is ABT in?
Abbott Laboratories is in the Healthcare sector, specifically the Medical Devices industry.
What is Abbott Laboratories's short interest?
As of the July 15, 2026 FINRA settlement, 24,846,147 ABT shares were sold short, or 1.42% of shares outstanding. Days to cover: 2.1. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Abbott Laboratories's revenue?
In its latest reported fiscal year (ending December 31, 2025), Abbott Laboratories reported revenue of $44.33B and net income of $6.52B.
Ask your own questions about ABT
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.